Stephen J Ralph

List of Publications by Year
in descending order

71 papers	6,347 citations	71004 43 h-index	93651 72 g-index
74 all docs	74 docs citations	74 times ranked	8785 citing authors

#	Article	IF	Citations
1	Targeting the redox imbalance in mitochondria: A novel mode for cancer therapy. Mitochondrion, 2022, 62, 50-73.	1.6	24
2	Tea tree oil extract causes mitochondrial superoxide production and apoptosis as an anticancer agent, promoting tumor infiltrating neutrophils cytotoxic for breast cancer to induce tumor regression. Biomedicine and Pharmacotherapy, 2021, 140, 111790.	2.5	7
3	Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. Expert Opinion on Investigational Drugs, 2020, 29, 311-326.	1.9	23
4	Repurposing drugs as proâ€oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers. Medicinal Research Reviews, 2019, 39, 2397-2426.	5.0	26
5	Use of antipsychotics and benzodiazepines for dementia: Time for action? What will be required before global de-prescribing?. Dementia, 2019, 18, 2322-2339.	1.0	13
6	Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. Journal of Alzheimer's Disease Reports, 2018, 2, 1-26.	1.2	104
7	Celecoxib inhibits mitochondrial O2 consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway. Biochemical Pharmacology, 2018, 154, 318-334.	2.0	51
8	Novel STAT binding elements mediate IL-6 regulation of MMP-1 and MMP-3. Scientific Reports, 2017, 7, 8526.	1.6	23
9	The in vitro and in vivo antiviral properties of combined monoterpene alcohols against West Nile virus infection. Virology, 2016, 495, 18-32.	1.1	24
10	Development of a potent melanoma vaccine capable of stimulating CD8+ T-cells independently of dendritic cells in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 861-872.	2.0	5
11	Redox state influence on human galectin-1 function. Biochimie, 2015, 116, 8-16.	1.3	14
12	Hitting the Bullâ€™s-Eye in Metastatic Cancersâ€”NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death. Pharmaceuticals, 2015, 8, 62-106.	1.7	37
13	Immunomodulatory activity of Melaleuca alternifolia concentrate (MAC): Inhibition of LPS-induced NF-Î°B activation and cytokine production in myeloid cell lines. International Immunopharmacology, 2015, 26, 257-264.	1.7	19
14	Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism. International Journal of Biochemistry and Cell Biology, 2014, 50, 10-23.	1.2	158
15	Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radical Biology and Medicine, 2014, 67, 41-50.	1.3	27
16	HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis, 2013, 34, 1699-1707.	1.3	153
17	Reactive oxygen species are generated by the respiratory complexÂ<scp>II</scp> â€“ evidence for lack of contribution of the reverse electron flow in complexÂ<scp>I</scp>. FEBS Journal, 2013, 280, 927-938.	2.2	60
18	Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion, 2013, 13, 199-208.	1.6	199

#	Article	IF	Citations
19	Human T Cell Leukemia Virus Type I Tax-Induced IÎºB-Î¶ Modulates Tax-Dependent and Tax-Independent Gene Expression in T Cells. Neoplasia, 2013, 15, 1110-1124.	2.3	10
20	REST Negatively and ISGF3 Positively Regulate the HumanSTAT1Gene in Melanoma. Molecular Cancer Therapeutics, 2013, 12, 1288-1298.	1.9	9
21	Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors. Current Pharmaceutical Biotechnology, 2013, 14, 357-376.	0.9	19
22	Molecular mechanism for the selective impairment of cancer mitochondrial function by a mitochondrially targeted vitamin E analogue. Biochimica Et Biophysica Acta - Bioenergetics, 2012, 1817, 1597-1607.	0.5	32
23	Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer and Metastasis Reviews, 2012, 31, 763-778.	2.7	104
24	Inhibiting galectin-1 reduces murine lung metastasis with increased CD4+ and CD8+ T cells and reduced cancer cell adherence. Clinical and Experimental Metastasis, 2012, 29, 561-572.	1.7	66
25	Hippo/Mst1 Stimulates Transcription of the Proapoptotic Mediator NOXA in a FoxO1-Dependent Manner. Cancer Research, 2011, 71, 946-954.	0.4	91
26	Anticancer Drugs Targeting the Mitochondrial Electron Transport Chain. Antioxidants and Redox Signaling, 2011, 15, 2951-2974.	2.5	79
27	The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?. Antioxidants and Redox Signaling, 2011, 15, 2989-3002.	2.5	8
28	Mitochondrial targeting of Î±-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy. Free Radical Biology and Medicine, 2011, 50, 1546-1555.	1.3	100
29	Inhibitors of Succinate: Quinone Reductase/Complex II Regulate Production of Mitochondrial Reactive Oxygen Species and Protect Normal Cells from Ischemic Damage but Induce Specific Cancer Cell Death. Pharmaceutical Research, 2011, 28, 2695-2730.	1.7	108
30	Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis, 2011, 14, 293-307.	3.7	84
31	Affinity of vitamin E analogues for the ubiquinone complex II site correlates with their toxicity to cancer cells. Molecular Nutrition and Food Research, 2011, 55, 1543-1551.	1.5	9
32	Mitochondrial Targeting of Vitamin E Succinate Enhances Its Pro-apoptotic and Anti-cancer Activity via Mitochondrial Complex II. Journal of Biological Chemistry, 2011, 286, 3717-3728.	1.6	171
33	Î±-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 782-794.	2.2	51
34	The determination of zinc, copper and iron oxidation state in invasive ductal carcinoma of breast tissue and normal surrounding tissue using XANES. X-Ray Spectrometry, 2010, 39, 332-337.	0.9	37
35	The Effect of Laser Irradiation on Proliferation of Human Breast Carcinoma, Melanoma, and Immortalized Mammary Epithelial Cells. Photomedicine and Laser Surgery, 2010, 28, 115-123.	2.1	43
36	Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Molecular Aspects of Medicine, 2010, 31, 29-59.	2.7	146

#	Article	IF	Citations
37	The causes of cancer revisited: â€œMitochondrial malignancyâ€•and ROS-induced oncogenic transformation â€“ Why mitochondria are targets for cancer therapy. Molecular Aspects of Medicine, 2010, 31, 145-170.	2.7	299
38	Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Letters, 2010, 299, 95-110.	3.2	91
39	HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1084-1101.	1.1	391
40	Suppression of Tumor GrowthIn vivoby the Mitocan Î±-tocopheryl Succinate Requires Respiratory Complex II. Clinical Cancer Research, 2009, 15, 1593-1600.	3.2	125
41	Mitochondria as targets for cancer therapy. Molecular Nutrition and Food Research, 2009, 53, 9-28.	1.5	83
42	Future use of mitocans against tumourâ€initiating cells?. Molecular Nutrition and Food Research, 2009, 53, 147-153.	1.5	7
43	Mitocans, a class of emerging antiâ€cancer drugs. Molecular Nutrition and Food Research, 2009, 53, 7-8.	1.5	81
44	Mitochondria as Targets for Cancer Therapy. , 2009, , 211-249.		1
45	Î±-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene, 2008, 27, 4324-4335.	2.6	266
46	Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action. Metal-Based Drugs, 2008, 2008, 1-13.	3.8	62
47	A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression. Cancer Research, 2007, 67, 3337-3344.	0.4	84
48	Vitamin E Analogs, a Novel Group of â€œMitocans,â€•as Anticancer Agents: The Importance of Being Redox-Silent. Molecular Pharmacology, 2007, 71, 1185-1199.	1.0	131
49	Vitamin E Analogues Inhibit Angiogenesis by Selective Induction of Apoptosis in Proliferating Endothelial Cells: The Role of Oxidative Stress. Cancer Research, 2007, 67, 11906-11913.	0.4	99
50	Tumour-initiating cells vs. cancer â€˜stemâ€™ cells and CD133: Whatâ€™s in the name?. Biochemical and Biophysical Research Communications, 2007, 355, 855-859.	1.0	176
51	Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria. Molecular Aspects of Medicine, 2007, 28, 607-645.	2.7	96
52	An Update on Malignant Melanoma Vaccine Research. American Journal of Clinical Dermatology, 2007, 8, 123-141.	3.3	20
53	Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. Journal of Bioenergetics and Biomembranes, 2007, 39, 65-72.	1.0	116
54	Molecular mechanism of â€˜mitocanâ€™-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Letters, 2006, 580, 5125-5129.	1.3	166

#	Article	IF	Citations
55	Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 327-346.	0.8	86
56	Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy. Current Pharmaceutical Design, 2005, 11, 3511-3530.	0.9	16
57	Inhibitory Effects Associated with Use of ModifiedPhotinus pyralisandRenilla reniformisLuciferase Vectors in Dual Reporter Assays and Implications for Analysis of ISGs. Journal of Interferon and Cytokine Research, 2005, 25, 92-102.	0.5	8
58	Enhancing CTL responses to melanoma cell vaccines in vivo : synergistic increases obtained using IFNÎ³ primed and IFNÎ² treated B7â€1 + B16â€F10 melanoma cells. Immunology and Cell Biology, 2003, 81, 459-471.	1.0	18
59	Isolation and Characterization of a Human STAT1Gene Regulatory Element. Journal of Biological Chemistry, 2002, 277, 19408-19417.	1.6	84
60	Bcl-2 and Mitochondrial Oxygen Radicals. Journal of Biological Chemistry, 1999, 274, 29831-29837.	1.6	160
61	IFI60/ISG60/IFIT4, a New Member of the Human IFI54/IFIT2 Family of Interferon-Stimulated Genes. Genomics, 1998, 54, 267-277.	1.3	53
62	Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3Î³. Journal of Biological Chemistry, 1997, 272, 28779-28785.	1.6	215
63	The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals. EMBO Journal, 1996, 15, 1075-84.	3.5	48
64	Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Letters, 1994, 339, 40-44.	1.3	371
65	Lipopolysaccharide- and interferon-gamma-induced expression of hck and lyn tyrosine kinases in murine bone marrow-derived macrophages. Oncogene, 1992, 7, 703-10.	2.6	104
66	Two isoforms of murine hck, generated by utilization of alternative translational initiation codons, exhibit different patterns of subcellular localization.. Molecular and Cellular Biology, 1991, 11, 4363-4370.	1.1	115
67	Alternatively spliced murine lyn mRNAs encode distinct proteins.. Molecular and Cellular Biology, 1991, 11, 3399-3406.	1.1	74
68	Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.. Molecular and Cellular Biology, 1991, 11, 2057-2065.	1.1	472
69	The application of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. Gene, 1989, 85, 67-74.	1.0	86
70	Structural Studies of T200 Glycoprotein and the Il-2 Receptor. Journal of Receptors and Signal Transduction, 1987, 7, 133-155.	1.2	3
71	Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb-IIIa glycoprotein complex. Blood, 1985, 66, 76-85.	0.6	2